Semin Vasc Med 2003; 03(4): 415-418
DOI: 10.1055/s-2004-817690

Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Antiplatelet Therapy for Elective Coronary Stenting: A Moving Target

Marc J. Claeys
  • Division of Cardiology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
Weitere Informationen


03. Februar 2004 (online)


The recognition of the major contribution of platelet-mediated mechanisms to the pathogenesis of thrombotic complications after coronary stenting has led to the development and evaluation of different antiplatelet regimens. The combination of aspirin and adenosine diphosphate antagonists such as ticlopidine and clopidogrel has solved the issue of acute stent thrombosis. The timing and dose of dual oral antiplatelet therapy have, however, changed over time with a shift from postintervention treatment to preintervention treatment with a high loading dose of clopidogrel. Pretreatment with aspirin and clopidogrel has been associated with a further 30% reduction in ischemic complications after coronary intervention. Recent data have even shown that in case of optimal pretreatment with such a dual oral antiplatelet therapy, glycoprotein IIb/IIIa antagonists are no longer mandatory for elective coronary stenting and should be reserved only for high-risk procedures or for acute coronary interventions.


  • 1 Gawaz M, Neumann F J, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.  Circulation . 1996;  94 279-285
  • 2 Cadroy Y, Bossavy J P, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans.  Circulation . 2000;  101 2823-2828
  • 3 Schomig A, Neumann F J, Kastrati A. et al . A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents N Engl J Med .  1996;  334 1084-1089
  • 4 Bertrand M E, Legrand V, Boland J. et al . Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.  Circulation . 1998;  98 1597-1603
  • 5 Urban P, Macaya C, Rupprecht H J. et al . Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).  Circulation . 1998;  98 2126-2132
  • 6 Leon M B, Baim D S, Popma J J. et al . A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators N Engl J Med .  1998;  339 1665-1671
  • 7 Bertrand M E, Rupprecht H J, Urban P, Gershlick A H, Investigators F. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).  Circulation . 2000;  102 624-629
  • 8 Savcic M, Hauert J, Bachmann F, Wyld P J, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.  Semin Thromb Hemost . 1999;  25 (suppl 2) 15-9
  • 9 Bhatt D L, Bertrand M E, Berger P B. et al . Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.  J Am Coll Cardiol . 2002;  39 9-14
  • 10 Steinhubl S R, Lauer M S, Mukherjee D P. et al . The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.  J Am Coll Cardiol . 1998;  32 1366-1370
  • 11 Mehta S R, Yusuf S, Peters R J. et al . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  Lancet . 2001;  358 527-533
  • 12 Steinhubl S R, Berger P B, Mann J T. et al . Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.  JAMA . 2002;  288 2411-2420
  • 13 Muller I, Seyfarth M, Rudiger S. et al . Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.  Heart . 2001;  85 92-93
  • 14 Claeys M J, Van Der Planken G M, Michiels J J. et al . Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.  Blood Coagul Fibrinolysis . 2002;  13 283-288
  • 15 Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.  Lancet . 1998;  352 87-92
  • 16 The Epic Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.  N Engl J Med . 1994;  330 956-961
  • 17 Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.  Lancet . 2000;  356 2037-2044
  • 18 Karvouni E, Katritsis D G, Ioannidis J P. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.  J Am Coll Cardiol . 2003;  41 26-32
  • 19 Topol E J, Moliterno D J, Herrmann H C. et al . Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.  N Engl J Med . 2001;  344 1888-1894
  • 20 Boersma E, Harrington R A, Moliterno D J, White H, Simoons M L. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.  Lancet . 2002;  360 342-343
  • 21 Steinhubl S R, Ellis S G, Wolski K, Lincoff A M, Topol E J. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial.  Circulation . 2001;  103 1403-1409
  • 22 Claeys M J, Van der Planken G M, Bosmans J M, Michiels J J, Vertessen F, Vrints C J. Is additional glycoprotein IIb/IIIa receptor inhibition useful in patients pretreated with clopidogrel and aspirin for elective coronary stenting?.  Eur Heart J . 2003;  24 475